Biogen Idec Inc. (ticker: BIIB, exchange: NASDAQ Global Market (.O))
News Release -
Biogen Idec and Elan Receive Notification of PDUFA Date Extension
WESTON, Mass. & DUBLIN, Oct 20, 2011 (BUSINESS WIRE) --
Idec (NASDAQ: BIIB) and Elan
Corporation, plc (NYSE: ELN) announced that the U.S. Food and Drug
Administration (FDA) has extended the initial PDUFA date for its review
of the supplemental Biologics License Application (sBLA) for TYSABRI(R)
(natalizumab). The sBLA was submitted in December 2010 to update the
Prescribing Information for TYSABRI to include anti-JC virus antibody
status as a factor to help stratify the risk of progressive multifocal
leukoencephalopathy (PML) in the TYSABRI-treated population. The 3 month
extension is a standard extension period.
The FDA has indicated that the extension of the PDUFA date is needed to
allow time for review of the changes being incorporated into the Risk
Evaluation and Mitigation Strategies (REMS) program for TYSABRI, to be
consistent with the anticipated Prescribing Information.
Biogen Idec and Elan are working with the FDA to help facilitate a
timely review of the REMS changes and the sBLA.
TYSABRI is approved in more than 60 countries. As a monotherapy, it is
approved in the U.S. for relapsing forms of MS, generally for patients
who have had an inadequate response to or are unable to tolerate an
alternative MS therapy. In the European Union, it is approved for highly
active RRMS in adult patients who have failed to respond to beta
interferon or have rapidly evolving severe RRMS.
TYSABRI has advanced the treatment of MS patients with its established
efficacy. It has been proven to reduce flare-ups and slow physical
disability progression. Data from the Phase III AFFIRM trial, which was
published in the New England Journal of Medicine, showed that after two
years, TYSABRI treatment led to a 68 percent relative reduction
(p<0.001) in the annualized relapse rate when compared with placebo and
reduced the relative risk of disability progression by 42-54 percent
TYSABRI increases the risk of progressive multifocal leukoencephalopathy
(PML), an opportunistic viral infection of the brain that usually leads
to death or severe disability. Other serious adverse events that have
occurred in TYSABRI-treated patients include hypersensitivity reactions
(e.g., anaphylaxis) and infections, including opportunistic and other
atypical infections. Clinically significant liver injury has also been
reported in patients treated with TYSABRI in the post-marketing setting.
Common adverse events reported in TYSABRI-treated MS patients include
headache, fatigue, infusion reactions, urinary tract infections, joint
and limb pain, and rash.
TYSABRI is co-marketed by Biogen Idec Inc. and Elan Corporation, plc.
For more information about TYSABRI, please visit www.tysabri.com,
or call 1-800-456-2255.
About Biogen Idec
Biogen Idec uses cutting-edge science to discover, develop, manufacture
and market therapies for serious diseases with a focus on neurology,
immunology and hemophilia. Founded in 1978, Biogen Idec is the world's
oldest independent biotechnology company. Patients worldwide benefit
from its leading multiple sclerosis therapies and the company generates
more than $4 billion in annual revenues. For product labeling, press
releases and additional information about the company, please visit www.biogenidec.com.
Elan Corporation, plc is a neuroscience-based biotechnology company
committed to making a difference in the lives of patients and their
families by dedicating itself to bringing innovations in science to fill
significant unmet medical needs that continue to exist around the world.
Elan shares trade on the New York and Irish Stock Exchanges. For
additional information about the Company, please visit www.elan.com.
SOURCE: Biogen Idec and Elan Corporation, plc
Jeff Boyle, + 1 781-464-3260
Elan Corporation, plc
Niamh Lyons, +353-1-709-4176
Kia Khaleghpour, +1 781-464-2442
Elan Corporation, plc
Chris Burns, +1 800-252-3526
David Marshall, +353 1 709-4444